Zentalis Pharmaceuticals’ (ZNTL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note released on Monday morning, MarketBeat reports. They currently have a $10.00 target price on the stock.

A number of other equities analysts have also weighed in on the stock. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, September 30th. They issued an “equal weight” rating and a $5.00 target price for the company. Mizuho started coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target on the stock. William Blair initiated coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They issued an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd. Finally, Wall Street Zen cut Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Zentalis Pharmaceuticals Stock Up 8.0%

Zentalis Pharmaceuticals stock opened at $2.30 on Monday. The stock has a market capitalization of $164.84 million, a PE ratio of -1.18 and a beta of 1.93. Zentalis Pharmaceuticals has a twelve month low of $1.21 and a twelve month high of $6.95. The company has a 50 day moving average of $3.26 and a 200-day moving average of $3.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Equities analysts anticipate that Zentalis Pharmaceuticals will post -2.11 EPS for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the acquisition, the insider directly owned 17,844,973 shares of the company’s stock, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ZNTL. Spark Investment Management LLC bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth about $61,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $126,000. Stonepine Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $783,678. Seven Fleet Capital Management LP grew its holdings in shares of Zentalis Pharmaceuticals by 188.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock valued at $1,451,000 after acquiring an additional 207,600 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $5,406,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.